How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
|Articles|November 10, 2011
Michael Blumenfield BIO (w/out pic)
Michael Blumenfield, MD is the Sidney E. Frank Distinguished Professor Emeritus of Psychiatry and Behavioral Sciences at New York Medical College; a past speaker of the Assembly of the American Psychiatric Association; and President-Elect of the American Academy of Psychoanalysis and Dynamic Psychiatry. He writes a blog, www.PsychiatryTalk.com, and contributes to the Psychiatric Times blog, “Couch in Crisis.” He is in private practice in Woodland Hills, Calif.
Advertisement
Michael Blumenfield, MD is the Sidney E. Frank Distinguished Professor Emeritus of Psychiatry and Behavioral Sciences at New York Medical College; a past speaker of the Assembly of the American Psychiatric Association; and President-Elect of the American Academy of Psychoanalysis and Dynamic Psychiatry. He writes a blog,
Advertisement
Related to this article
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Makes Us Human? The Role of Psychiatry and the Future DSM
2
The First Ever Treatment-Resistant Depression Awareness Day
3
Relief Is Not Free: A Case Study of Athlete Cannabis Use
4
How Best to Manage Treatment-Resistant Depression
5